{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:01:54Z","timestamp":1784656914881,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,7]]},"DOI":"10.7759\/cureus.46646","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T18:06:41Z","timestamp":1696702001000},"source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of HER2Neu Status in Periampullary Cancers in Tertiary Care Centre in Northern India: A Three-Year Retrospective Study"],"prefix":"10.7759","author":[{"given":"Sumaira","family":"Qayoom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorva","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2008.01.030","article-title":"An audit of outcomes of a series of periampullary carcinomas","volume":"35","author":"Berberat PO","year":"2009","unstructured":"Berberat PO, K\u00fcnzli BM, Gulbinas A, et al.. An audit of outcomes of a series of periampullary carcinomas. Eur J Surg Oncol. 2009, 35:187-91. 10.1016\/j.ejso.2008.01.030","journal-title":"Eur J Surg Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-004-0894-7","article-title":"Neoplastic diseases of the papilla of Vater","volume":"11","author":"Kimura W","year":"2004","unstructured":"Kimura W, Futakawa N, Zhao B. Neoplastic diseases of the papilla of Vater. J Hepatobiliary Pancreat Surg. 2004, 11:223-31. 10.1007\/s00534-004-0894-7","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1593\/neo.04445","article-title":"Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis","volume":"7","author":"L\u00f6hr M","year":"2005","unstructured":"L\u00f6hr M, Kl\u00f6ppel G, Maisonneuve P, Lowenfels AB, L\u00fcttges J. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia. 2005, 7:17-23. 10.1593\/neo.04445","journal-title":"Neoplasia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i14.2162","article-title":"Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer","volume":"11","author":"Dong M","year":"2005","unstructured":"Dong M, Ma G, Tu W, Guo KJ, Tian YL, Dong YT. Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer. World J Gastroenterol. 2005, 11:2162-5. 10.3748\/wjg.v11.i14.2162","journal-title":"World J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/ng1215","article-title":"Chromosome aberrations in solid tumors","volume":"34","author":"Albertson DG","year":"2003","unstructured":"Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet. 2003, 34:369-76. 10.1038\/ng1215","journal-title":"Nat Genet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(93)90194-l","article-title":"Overexpression of HER-2\/neu oncogene in human pancreatic carcinoma","volume":"24","author":"Yamanaka Y","year":"1993","unstructured":"Yamanaka Y, Friess H, Kobrin MS, M B\u00fcchler, J Kunz, H G Beger, M Korc. Overexpression of HER-2\/neu oncogene in human pancreatic carcinoma. Hum Pathol. 1993, 24:1127-34. 10.1016\/0046-8177(93)90194-l","journal-title":"Hum Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711610305","article-title":"The c-erb B-2 proto-oncogene in human pancreatic cancer","volume":"161","author":"Hall PA","year":"1990","unstructured":"Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, Lemoine NR. The c-erb B-2 proto-oncogene in human pancreatic cancer. J Pathol. 1990, 161:195-200. 10.1002\/path.1711610305","journal-title":"J Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930701)72:1<51::aid-cncr2820720112>3.0.co;2-o","article-title":"An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucinhypersecreting neoplasms and in ductal cell carcinomas of the pancreas","volume":"72","author":"Satoh K","year":"1993","unstructured":"Satoh K, Sasano H, Shimosegawa T, et al.. An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucinhypersecreting neoplasms and in ductal cell carcinomas of the pancreas. Cancer. 1993, 72:1-51. 10.1002\/1097-0142(19930701)72:1&lt;51::aid-cncr2820720112&gt;3.0.co;2-o","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/BF02788354","article-title":"Overexpression of HER2\/neu oncogene in pancreatic cancer correlates with shortened survival","volume":"17","author":"Lei S","year":"1995","unstructured":"Lei S, Appert HE, Nakata B, Domenico DR, Kim K, Howard JM. Overexpression of HER2\/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Pancreatol. 1995, 17:15-21. 10.1007\/BF02788354","journal-title":"Int J Pancreatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal N","year":"2014","unstructured":"Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014, 2014:852748. 10.1155\/2014\/852748","journal-title":"Mol Biol Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.53.5.374","article-title":"Laboratory assessment of the status of Her-2\/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays","volume":"53","author":"Wang S","year":"2000","unstructured":"Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of Her-2\/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol. 2000, 53:374-81. 10.1136\/jcp.53.5.374","journal-title":"J Clin Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1054\/modi.2000.16690","article-title":"HER-2\/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival","volume":"5","author":"Kakar S","year":"2000","unstructured":"Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, Mihalov ML. HER-2\/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn. 2000, 5:199-207. 10.1054\/modi.2000.16690","journal-title":"Mol Diagn"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880505","article-title":"Aneusomy 17 in breast cancer: its role in HER-2\/neu protein expression and implication for clinical assessment of HER-2\/neu status","volume":"15","author":"Wang S","year":"2002","unstructured":"Wang S, Hossein Saboorian M, Frenkel EP, et al.. Aneusomy 17 in breast cancer: its role in HER-2\/neu protein expression and implication for clinical assessment of HER-2\/neu status. Mod Pathol. 2002, 15:137-45. 10.1038\/modpathol.3880505","journal-title":"Mod Pathol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.142","article-title":"Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma","volume":"22","author":"Stoecklein NH","year":"2004","unstructured":"Stoecklein NH, Luebke AM, Erbersdobler A, et al.. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J Clin Oncol. 2004, 22:4737-45. 10.1200\/JCO.2004.05.142","journal-title":"J Clin Oncol"},{"key":"ref15","article-title":"HER2\/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis","volume":"7","author":"Tsiambas E","year":"2006","unstructured":"Tsiambas E, Karameris A, Dervenis C, Lazaris AC, Giannakou N, Gerontopoulos K, Patsouris E. HER2\/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP. 2006, 7:283-94.","journal-title":"JOP"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200110000-00016","article-title":"Overexpression of the HER-2\/neu oncogene in pancreatic adenocarcinoma","volume":"24","author":"Safran H","year":"2001","unstructured":"Safran H, Steinhoff M, Mangray S, et al.. Overexpression of the HER-2\/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol. 2001, 24:496-9. 10.1097\/00000421-200110000-00016","journal-title":"Am J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/gm482. eCollection 2013","article-title":"Clinical and molecular characterization of HER2 amplified-pancreatic cancer","volume":"2013","author":"Chou A","unstructured":"Chou A, Waddell N, Cowley MJ, et al.. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med. 2013:78. 10.1186\/gm482. eCollection 2013","journal-title":"Genome Med"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1309\/P3CHDX9LY6H2LY0G","article-title":"A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2\/neu: use of immunolabeling and multicolor FISH for potential patient screening andtreatment","volume":"123","author":"Hansel DE","year":"2005","unstructured":"Hansel DE, Ashfaq R, Rahman A, Wanzer D, Yeo CJ, Wilentz RE, Maitra A. A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2\/neu: use of immunolabeling and multicolor FISH for potential patient screening andtreatment. Am J Clin Pathol. 2005, 123:28-35.","journal-title":"Am J Clin Pathol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-008-0267-1","article-title":"HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma","volume":"53","author":"Sharif S","year":"2008","unstructured":"Sharif S, Ramanathan RK, Potter D, Cieply K, Krasinskas AM. HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma. Dig Dis Sci. 2008, 53:3026-32. 10.1007\/s10620-008-0267-1","journal-title":"Dig Dis Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01176.x","article-title":"HER2 overexpression correlates with survival after curative resection of pancreatic cancer","volume":"100","author":"Komoto M","year":"2009","unstructured":"Komoto M, Nakata B, Amano R, et al.. HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci. 2009, 100:1243-7. 10.1111\/j.1349-7006.2009.01176.x","journal-title":"Cancer Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9541-0","article-title":"Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors","volume":"30","author":"Galsky MD","year":"2012","unstructured":"Galsky MD, Von Hoff DD, Neubauer M, et al.. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs. 2012, 30:695-701. 10.1007\/s10637-010-9541-0","journal-title":"Invest New Drugs"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.18","article-title":"Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer","volume":"106","author":"Harder J","year":"2012","unstructured":"Harder J, Ihorst G, Heinemann V, et al.. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer. 2012, 106:1033-8. 10.1038\/bjc.2012.18","journal-title":"Br J Cancer"},{"key":"ref23","article-title":"Expression of p21(Wafl\/Cip1), p57(Kip2) and HER2\/neu in patients with gallbladder cancer","volume":"27","author":"Puhalla H","year":"2007","unstructured":"Puhalla H, Wrba F, Kandioler D, et al.. Expression of p21(Wafl\/Cip1), p57(Kip2) and HER2\/neu in patients with gallbladder cancer. Anticancer Res. 2007, 27:1679-84.","journal-title":"Anticancer Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa D","year":"2008","unstructured":"Yoshikawa D, Ojima H, Iwasaki M, et al.. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008, 98:418-25. 10.1038\/sj.bjc.6604129","journal-title":"Br J Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.4511","article-title":"EGFR and HER2 expression in advanced biliary tract cancer","volume":"15","author":"Harder J","year":"2009","unstructured":"Harder J, Waiz O, Otto F, et al.. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol. 2009, 15:4511-7. 10.3748\/wjg.15.4511","journal-title":"World J Gastroenterol"},{"key":"ref26","article-title":"Overexpression of the HER2\/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer","volume":"7","author":"Roa I","year":"2014","unstructured":"Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, Javle M. Overexpression of the HER2\/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer. Gastrointest Cancer Res. 2014, 7:42-8.","journal-title":"Gastrointest Cancer Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-631","article-title":"Targeting EGFR\/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas","volume":"10","author":"Pignochino Y","year":"2010","unstructured":"Pignochino Y, Sarotto I, Peraldo-Neia C, et al.. Targeting EGFR\/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010, 10:631. 10.1186\/1471-2407-10-631","journal-title":"BMC Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2009.10.002","article-title":"Epidermal growth factor receptor and HER-2\/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder","volume":"41","author":"Shafizadeh N","year":"2010","unstructured":"Shafizadeh N, Grenert JP, Sahai V, Kakar S. Epidermal growth factor receptor and HER-2\/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. Hum Pathol. 2010, 41:485-92. 10.1016\/j.humpath.2009.10.002","journal-title":"Hum Pathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/184770-evaluation-of-her2neu-status-in-periampullary-cancers-in-tertiary-care-centre-in-northern-india-a-three-year-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:58Z","timestamp":1707509278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/184770-evaluation-of-her2neu-status-in-periampullary-cancers-in-tertiary-care-centre-in-northern-india-a-three-year-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,7]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.46646","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,7]]}}}